债券简称：华海转债 债券代码：110076 股票简称：华海药业 股票代码：600521 公告编号：临 2024-047 号 （二）本次增持计划实施前，陈保华先生合计持有公司股份 365,697,935 股，占 公司总股本的比例为 24.67%； （三）增持主体陈保华先生在本次增持计划公告披露前十二个月内无已披露的增 持计划，且在该增持计划公告披露前六个月内不存在减持公司股份的情况。 浙江华海药业股份有限公司 关于控股股东增持公司股份计划实施结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 浙江华海药业股份有限公司（以下简称"公司"）于 2023 年 10 月 31 日披露了 《浙江华海药业股份有限公司关于控股股东增持公司股份计划公告》（公告编号：临 2023-109 号），基于对公司未来发展前景的信心及长期投资价值的认可，公司控股股 东及实际控制人陈保华先生计划自增持计划披露之日起 6 个月内，拟通过上海证券交 易所系统集中竞价交易方式增持公司股份，增持金额不低于人民币 2,000 万元，不 ...

Financial Performance - The company achieved operating revenue of CNY 8,308,719,758.46 in 2023, a year-on-year increase of 0.52%[19]. - The net profit attributable to shareholders was CNY 830,466,003.18, representing a decline of 28.88% compared to the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 888,522,218.59, down 25.96% year-on-year[19]. - The net cash flow from operating activities increased by 78.40% to CNY 2,217,021,274.88[19]. - The company's total assets at the end of 2023 were CNY 18,599,969,612.84, a 2.47% increase from the previous year[19]. - Basic earnings per share decreased by 29.63% to CNY 0.57 in 2023[20]. - The weighted average return on net assets was 10.64%, down 5.91 percentage points from the previous year[20]. - The company reported a total of CNY 2,101,155,202.27 in operating revenue for Q4 2023[22]. - The total revenue for the company reached CNY 8,249,178,955.91, with a year-on-year increase of 0.81%[63]. - The gross profit margin decreased by 1.99 percentage points compared to the previous year, primarily due to the impact of domestic procurement policies leading to lower prices[63]. - Revenue from finished drug sales amounted to CNY 4,931,569,375.42, reflecting a year-on-year increase of 4.46%[63]. - The revenue from technical services surged by 264.60% year-on-year, totaling CNY 122,163,764.93[63]. - Domestic revenue was CNY 4,036,320,572.33, showing a decline of 4.45% year-on-year[63]. - International revenue reached CNY 4,212,858,383.58, with a year-on-year increase of 6.42%[63]. Research and Development - The company is focusing on upgrading its R&D strategy and expanding its product categories to enhance market competitiveness[26]. - R&D investment accounted for 14.08% of revenue, with 15 new domestic formulation approvals and 20+ ongoing projects in biopharmaceuticals[30]. - The company has 20+ ongoing biopharmaceutical projects, with 11 entering clinical research stages, focusing on unmet clinical needs[30]. - The company is focusing on the development of innovative drugs in the fields of autoimmune diseases and oncology, with over 40 domestic and international invention patents applied and more than 20 projects currently under research[39]. - The company has a robust pipeline with several drugs at different stages of development, indicating a strong commitment to research and development[103]. - The company reported a total investment loss of 78,119,814.57 RMB for the period, with a fair value change loss of 46,198,316.37 RMB from its investment in Junshi Bioscience (688180) and 19,356,244.33 RMB from its investment in Amgen Pharmaceuticals (688373)[116]. - The company is actively involved in the research and development of pharmaceutical products, including the production of various monoclonal antibodies[123]. - The company has received FDA orphan drug designation for HB0034, indicating its potential significance in treating rare diseases[92]. Market Expansion and Strategy - The company is actively expanding its sales network in Belt and Road countries, aiming to capture more commercial opportunities[28]. - The company is committed to building a core competitive product pipeline by increasing the development of generic and first-generic drugs[130]. - The company aims to achieve sustainable growth by balancing internal growth and external expansion, enhancing its brand reputation and industry influence[128]. - The company plans to strengthen its innovation technology system and accelerate the pace of new product development, focusing on key research areas and aligning with international advanced levels[129]. - The company is focusing on enhancing its market presence through strategic expansions and product diversification[84]. - The company aims to enhance its global marketing system and create a strategic operational ecosystem focused on expanding its market share in both domestic and international markets[130]. Corporate Governance - The company has established a robust internal control management system in compliance with relevant laws and regulations[187]. - The company held three shareholder meetings during the reporting period, ensuring broad participation and adherence to legal requirements[148]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with relevant laws and regulations[148]. - The company has implemented strict insider information management to protect shareholder rights[149]. - The company has conducted training for employees to enhance awareness of insider information confidentiality[149]. - The company has established a scientific performance evaluation system linked to employee compensation and promotions, enhancing talent retention and governance[148]. Environmental and Safety Compliance - The company has increased its investment in safety and environmental protection facilities to enhance compliance and risk prevention capabilities[142]. - The company has implemented a comprehensive environmental protection mechanism as a key pollutant discharge unit[190]. - The company achieved a total COD discharge limit of 8.194 tons and ammonia nitrogen of 0.41 tons, meeting regulatory standards in 2023[190]. - The company operates a total of 1 wastewater discharge outlet located in the northern area of the plant, along with 12 gas discharge outlets, of which 2 are under construction[194]. - The total nitrogen oxides emissions for Zhejiang Huahai Pharmaceutical Co., Ltd. are capped at 6.465 tons for 2023, with actual emissions within the permitted range[194]. Talent and Workforce - The company has a strong talent pool, including over 100 high-level talents with overseas backgrounds, supporting its R&D capabilities[57]. - The number of R&D personnel is 1,848, accounting for 22.48% of the total workforce[73]. - The company has 113 employees with a doctoral degree and 707 with a master's degree, indicating a strong educational background among its workforce[176]. - The company has established a comprehensive talent training mechanism to support its rapid development and enhance its competitive strength[33]. Shareholder Returns - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on the total share capital after deducting shares held in the repurchase account[4]. - The total cash dividend amount for 2022 was approximately 354.54 million CNY, representing 42.69% of the net profit attributable to ordinary shareholders[182]. - The company’s cash dividend for 2022 was 0.24 CNY per share, which was implemented on July 3, 2023[179]. - The company plans to distribute a cash dividend of 0.2 CNY per share for the 2023 fiscal year, pending shareholder approval[179].

Financial Performance - The company's operating revenue for Q1 2024 reached ¥2,498,671,124.15, representing a year-on-year increase of 21.36%[4] - Net profit attributable to shareholders was ¥270,842,789.22, reflecting a significant growth of 56.62% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥315,424,401.91, an increase of 67.29% year-on-year[4] - Basic and diluted earnings per share were both ¥0.19, up by 58.33% year-on-year[4] - Total operating revenue for Q1 2024 reached RMB 2,498,671,124.15, a 21.3% increase from RMB 2,058,913,113.43 in Q1 2023[16] - Net profit for Q1 2024 was RMB 273,944,434.55, representing a 62.7% increase compared to RMB 168,505,392.26 in Q1 2023[17] - The company reported a total profit of RMB 371,845,376.74 for Q1 2024, compared to RMB 240,883,645.68 in Q1 2023, marking a 54.4% increase[17] - The total comprehensive income for Q1 2024 was CNY 262,178,448.31, compared to CNY 148,538,126.97 in Q1 2023[25] Cash Flow - The net cash flow from operating activities was ¥853,246,043.03, showing a remarkable increase of 128.18% compared to the previous year[4] - Cash flow from operating activities generated RMB 853,246,043.03, significantly higher than RMB 373,933,429.54 in Q1 2023[19] - The net cash flow from investing activities was -471,690,659.45 RMB, a decrease from -521,104,230.29 RMB year-over-year[20] - The company reported a net cash flow from financing activities of 1,093,031,459.41 RMB, significantly higher than 548,627,492.74 RMB in the same quarter last year[20] - The net increase in cash and cash equivalents for the quarter was 1,485,562,536.52 RMB, compared to 367,599,362.76 RMB in the previous year[20] - The company's cash inflow from financing activities totaled 1,838,330,000.00 RMB, compared to 1,440,000,000.00 RMB in the previous year[20] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥20,089,317,179.86, an increase of 8.01% from the end of the previous year[4] - The company's total assets amounted to ¥20,089,317,179.86, compared to ¥18,599,969,612.84 at the end of 2023, reflecting a growth of approximately 8.0%[15] - Total current assets reached ¥8,901,797,081.57, up from ¥7,621,698,796.25, indicating an increase of about 16.8%[13] - The total liabilities increased to ¥11,599,242,747.86 from ¥10,348,854,672.57, which is an increase of approximately 12.1%[15] - The total liabilities increased to 8,776,729,779.72 RMB from 7,713,638,601.41 RMB year-over-year[22] - The company's equity attributable to shareholders rose to ¥8,319,436,460.31 from ¥8,076,851,901.19, showing an increase of about 3.0%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 72,310, with the top ten shareholders holding significant stakes[8] - The company has not reported any new strategies or significant changes in shareholder structure during the reporting period[12] Expenses - Total operating costs increased to RMB 2,099,036,620.37, up 17.1% from RMB 1,791,603,923.39 in the same period last year[16] - Research and development expenses for Q1 2024 were RMB 213,856,487.20, slightly up from RMB 202,193,404.97 in Q1 2023[16] - Sales expenses increased to RMB 490,541,619.20, a rise of 42.4% from RMB 344,775,680.27 in the previous year[16] - The company reported a financial expense of CNY 20,187,931.25 in Q1 2024, significantly reduced from CNY 68,797,147.86 in Q1 2023[24] Inventory and Investments - The company reported a total inventory of ¥3,236,962,151.59, down from ¥3,432,132,350.93, indicating a decrease of approximately 5.7%[13] - The company's inventory decreased to 2,330,768,586.18 RMB from 2,477,827,713.94 RMB year-over-year[21] - Long-term equity investments slightly decreased to ¥410,319,572.86 from ¥417,871,184.53, reflecting a decline of about 1.3%[14] - Long-term equity investments increased to 6,737,584,700.08 RMB from 6,586,268,218.76 RMB year-over-year[21] Market and Strategy - The sales team restructuring and market expansion efforts have led to improved market penetration and customer retention, contributing to revenue growth[7] - There were no new products or technologies announced in the current quarter[12]

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2024-033 | 号 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的白消安注射液的《药品注册证书》，现 将相关情况公告如下： 一、药品的基本情况 药品名称：白消安注射液 剂型：注射剂 规格：10ml：60mg 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 申请人：浙江华海药业股份有限公司 药品批准文号：国药准字 H20243505 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 白消安注射液适用于联合环磷酰胺，作为慢性髓性白血病同种异体的造 ...

浙江华海药业股份有限公司（以下简称公司）于2024年3月22日披露的《关于归还募集资金的公告》显示，部分 暂时用于补充流动资金的闲置募集资金使用期限已超过十二个月，涉及金额1,150万元。 公司上述行为违反《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》（证监会公告 〔2022〕15号）第九条、《上市公司信息披露管理办法》（证监会令第182号）第三条的规定。公司董事长李宏、总 经理陈保华、首席财务官张美、董事会秘书祝永华违反《上市公司信息披露管理办法》（证监会令第182号）第四 条、第五十一条的规定，对上述违规行为承担主要责任。根据《上市公司信息披露管理办法》（证监会令第182号） 第五十二条的规定，我局决定对你们分别采取出具警示函的监督管理措施，并记入证券期货市场诚信档案。你们应严 格遵守有关法律法规，提高规范运作意识，杜绝类似情况再次发生。请你们在收到本决定书之日起10个工作日内向我 局提交书面报告。 如果对本监督管理措施不服的，可以在收到本决定书之日起60日内向中国证券监督管理委员会提出行政复议申 请，也可以在收到本决定书之日起6个月内向有管辖权的人民法院提起诉讼。复议与诉讼期间，上述 ...

24年4月16 : (以 )于 2024 3月 22日 ,部 ,涉 1,150万 2号 (证 E2022〕 15号 )第 (证 182号 )第 (证 182号 )第 ,对 (证 182号 )第 , 我局决定对你们分别采取出具警示函的监督管理措施,并记 入证券期货市场诚信档案。你们应严格遵守有关法律法规, 提高规范运作意识,杜绝类似情况再次发生。请你们在收到 本决定书之日起 10个工作日内向我局提交书面报告。 如果对本监督管理措施不服的,可以在收到本决定书之 日起 60 日内向中国证券监督管理委员会提出行政复议申请, 也可以在收到本决定书之日起6个月内向有管辖权的人民法 院提起诉讼。复议与诉讼期间,上述监督管理措施不停止执 行。 E2024〕 45号 浙江证监局办公室 2024年4月16日印发 共印7份 - 2 - ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2024-032 | 号 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 关于公司及相关人员收到浙江证监局警示函的公告 1、上述《决定书》中所述公司超期使用闲置募集资金补充流动资金事项，公 司已于 2024 年 3 月 23 日在上海证券交易所网站 www.sse.com.cn 上披露了《浙江 华海药业股份有限公司关于归还募集资金的公告》（公告编号：临 2024-021 号）。 2、公司及相关人员高度重视《决定书》中提及的募集资金规范使用相关事项， 1 公司自查发现上述情况后，立即归还了该部分募集资金。公司将进一步加强公司募 集资金管控措施，深化交叉提醒监督机制，同时公司将进一步加强组织董事、监事、 高级管理人员以及募集资金管理人员等各级相关人员对《上市公司监管指引第 2 号 ——上市公司 ...

证券代码：600521 证券简称：华海药业 公告编号：临 2024-031 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于股份回购实施结果暨股份变动的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江华海药业股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日提交 披露了《浙江华海药业股份有限公司关于股份回购实施结果暨股份变动公告》。 因工作人员疏忽，将下述表格中的"预计回购金额"单位"万元"误填写为"元"， 现更正如下： | 回购方案首次披露日 | 2023/11/7 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2023 | 11 | 6 | 日~2024 | 年 | 11 | 月 5 | 日 | | 预计回购金额 | 元 5,000 元~10,000 | | | | | | | | | 回购价格上限 | 元/股 24.49 | | | ...

重要内容提示： | 回购方案首次披露日 | 2023/11/7 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2023 年 月 6 日~2024 年 11 | 11 | 月 | 5 日 | | 预计回购金额 | 元 5,000 元~10,000 | | | | | 回购价格上限 | 元/股 24.49 | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 实际回购股数 | 股 7,023,600 | | | | | 实际回购股数占总股本比例 | 0.4738% | | | | | 实际回购金额 | 元 99,992,566.83 | | | | | 实际回购价格区间 | 元/股~15.79 元/股 12.36 | | | | 一、 回购审批情况和回购方案内容 浙江华海药业股份有限公司（以下简称"公司"）于 2023 年 11 月 6 日召开第 八届董事会第十九次临时会议、第八届监事会第十二次临时会议，会议均审议通 过《关于以集中竞价 ...

证券代码：600521 证券简称：华海药业 公告编号：临 2024-029 号 债券代码：110076 债券代码：华海转债 浙江华海药业股份有限公司 关于股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 浙江华海药业股份有限公司（以下简称"公司"）5%以上股东周明华先生持 有公司股份总数为 224,418,890 股，占公司总股本的比例为 15.14%。本次部分股 份质押完成后，周明华先生处于质押状态的股份累计数为 98,000,000 股，占其所 持公司股份总数的 43.67%，占本公司总股本的比例为 6.61%。 公司于近日收到持有公司 5%以上股份的股东周明华先生关于其部分股份质 押的通知，现将具体情况公告如下： | 股东 | 是否为 | 本次质押股 | 是否 | 是否 | 质押起始 | 质押到期 | | 占其所 | 占公司 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 ...